Innovia Medical Expands Single-Use Instrument Product Line into the US with Gynecology Product Cervical Rotating Biopsy Punch

Innovia Medical (“Innovia”) is thrilled to announce the expansion of their single-use instrument product line into the U.S. The product leading the expansion is a gynecology product called the Cervical Rotating Biopsy Punch which supports urgently needed procedures like cancer diagnosis.

The single-use instrument was first introduced by DTR Medical Ltd (“DTR Medical”) in Wales in 2012 is now offered by Summit Medical LLC. (“Summit Medical”), a Minnesota based manufacturer of medical devices.

Since the initial development of the Cervical Rotating Biopsy Punch, the product has been used by numerous National Health Service (NHS) clinics and hospitals in the U.K. that have provided annual product feedback allowing for continuous product innovations. As part of an ongoing project with a leading Welsh University, a pioneering technique, known as biorefining, was used to recreate low carbon technologies for both the Cervical Rotating Biopsy Punch and it’s packaging. The instrument handle is now made of 20% renewably sourced propanediol (PDO) made from corn starch, making it both lightweight and recyclable. The polybag packaging was biorefined in 2020 to save 1,200 pounds of plastic each year. The Cervical Rotating Biopsy Punch has 2.8 times less of an environmental impact than other single-use products on the market like the metal Tischler Cervical Biopsy Punch and Baby Tischler Cervical Biopsy Punch.

Single-use instruments like the Cervical Rotating Biopsy Punch eliminate cross contamination, inadequate samples and repeat procedures. With Cervical cancer screenings down 68% in the U.S. due to COVID-19 [1], the importance of an adequate biopsy is essential in reducing the time to an accurate diagnosis.

“We believe introducing the Cervical Rotating Biopsy Punch to the U.S. is a natural expansion of our Single-Use Instrument category. Immediate benefits will improve the quality of patient care from acute care facilities to small offices that lack reprocessing environments. The quality of biopsy is notable and user feedback over the past decade has been extremely positive.” Said Marcus Super, Vice President of Marketing at Innovia Medical.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”